Our latest paper ist out in Histopathology ! We comprehensively studied the membranous protein expression of the two important #ADC targets TROP2 and NECTIN4 (surfaceome 🏄‍♂️). it is the first paper on protein expression in a large cohort of over 200 muscle-invasive and metastic

Long Term results from PROFOUND out. Clearly showing the tremendous (🧪) predictive potential of deleterious BRCA alterations for PARP inhibitor Olaparib in metastatic castration resistant #prostatecancer!! Although certainly not powered for that: ‼️ germline BRCA patients tend

Prediction of therapy response based on RECIST criteria only has limitations for the immunotherapy era! Longitudinal assessment of simple inflammatory 🔥blood biomarkers (CRP + albumin integrated into modified Glasgow Prognostic Score/ mGPS) provides complementary information

Throwback Thursday: Different Responses to Neoadjuvant Chemotherapy in Urothelial Carcinoma Molecular Subtypes buff.ly/3CqNcJr Gottfrid Sjödahl fredrik liedberg

Sacituzumab + Pembro is efficacious in metastic urothelial cancer following progress on platinum based chemotherapy !! Very interesting study by Petros Grivas and Yohann Loriot and team that unfortunately comes late. Is there still a place for this regimen after EV302 results ? But

Great to see EV-302 data finally published NEJM! Big step for patients with metastatic UC with doubling in OS! ➡️Open questions are which patients in particular benefit from EV/P and which patients only achieve short-term response or have primary EV/P resistance? ➡️Prediction

⚡️ On @nejm - Enfortumab Vedotin and Pembrolizumab — A New Perspective on Urothelial Cancer #BladderCancer #Immunotherapy Tom Powles Shilpa Gupta Daniel Castellano OncoAlert nejm.org/doi/full/10.10…

Excited to share our new paper just published Nature Communications WCM GU Cancer Weill Cornell Medicine nature.com/articles/s4146… Great collaboration between my lab with Olivier Elemento WCM Englander Institute for Precision Medicine and J.M. Mosquera Weill Cornell Medicine Pathology 🔬 Full tweetorial below with more updates to come. Stay tuned!

Happy to share or words of wisdom commentary European Urology about ADC development for Penile squamous cell carcinoma (PSCC)! Johannes Linxweiler Markus Eckstein European Association of Urology (EAU) ➡️Targeting common antigens like TROP2 or NECTIN-4 is a promising avenue to develop tumor-agnostic ADC treatment in

Nectin-4—drug conjugates (in metastatic urothelial carcinomas): The right drug for everyone? Happy to talk about current evidence to use Nectin-4 status to predict Enfortumab vedotin response in met. UC at #EAU24 in Paris European Association of Urology (EAU) ! Very interesting Session on saturday about

What a start at #EAU24 - OS Update of CheckMate274 Adjuvant Nivolumab demonstrates OS benefit for high-risk MIBC, especially in PD-L1+ population! (HR 0.56) brando But: Why did adjuvant Nivo perform better than Pembro (AMBASSADOR did not demonstrate OS benefit ASCO

New data from EV302 Enfortumab Vedotin & pembrolizumab for upper tract disease (~25% of pts). UTUC has distinct biological features including more FGFR alterations. PFS & OS HR of 0.50 & 0.53 respectively in the subset is in line with the whole population (0.45 and 0.47) #EAU24

💉🩸High serum sodium predicts response to IO in mUC and mRCC EORTC @OncologyAdvance ➡️Posthoc analyses of IMvigor211 (mUC, atezolizumab) and IMmotion151 (mRCC, atezolizumab+bevacizumab) trials ✅Baseline serum sodium levels of >140mmol/L : higher objective response⬆️ ✅Serum

We are happy to share our current manuscript: In an exploratory post-hoc analysis of IMmotion151 (mRCC, atezo + beva) and IMvigor211 (mUC, atezo), in which we correlated baseline electrolyte concentration with ICB response and outcome in an unbiased manner, we made an interesting

Interesting work from Niklas Klümper et al —Na levels may module ICB response. Still so much unknown in this area. Congrats for the elegant work Niklas!

Thrilled to share our review published today in Nature Reviews Urology! Nature Reviews Urology: rdcu.be/dYuu1 "Pre-treatment metastatic biopsy: a step towards precision oncology for urothelial cancer" Thanks to the amazing team of collaborators Alexander Cox Gottfrid Sjödahl

Excited to be part of this exciting review Nat Rev Neurology "Pre-treatment metastatic biopsy: a step towards precision oncology for urothelial cancer" with Niklas Klümper Alexander Cox Gottfrid Sjödahl @roghmann Viktor Grünwald Michael Hölzel Markus Eckstein

Are pre-treatment #biopsies the way to go in mUC? ☑️Response prediction to immunotherapy, anti-NECTIN4 ADC enfortumab vedotin, FGFR inhibitor erdafitinib ☑️Identification of druggable alterations and treatment selection Markus Eckstein Niklas Klümper OncoDaily #BladderCancer

📹 How can artificial intelligence improve our understanding of tumour complexity? Dr. Benjamin Pradere interviews Dr. Markus Eckstein on how AI is speeding up the process of diagnosis. But what next? And what about AI for #bladdercancer pathology? 👇 bladder.uroonco.uroweb.org/video/how-ai-c…

Starting soon #EAU25 #BPH GAME CHANGER session - late breaking release of WATER3 RCT HOLEP vs Aquablation Therapy PROCEPT BioRobotics - 1015-1030am Green area. Is Aquablation as effective, efficient and safe for prostates 80-180cc? Come find out!